{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:42:04Z","timestamp":1785400924302,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00259-025-07471-0","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:24:14Z","timestamp":1754371454000},"page":"876-889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheres"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-9881","authenticated-orcid":false,"given":"Ammar","family":"Sarwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Odeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsa","family":"Babar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Eckhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeb","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"7471_CR1","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1148\/RADIOL.2018171768","volume":"287","author":"RJ Lewandowski","year":"2018","unstructured":"Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287:1050\u20138. https:\/\/doi.org\/10.1148\/RADIOL.2018171768.","journal-title":"Radiology"},{"key":"7471_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"7471_CR3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/HEP.29691","volume":"68","author":"R Salem","year":"2018","unstructured":"Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology (Baltimore MD). 2018;68:1429\u201340. https:\/\/doi.org\/10.1002\/HEP.29691.","journal-title":"Hepatology (Baltimore MD)"},{"key":"7471_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/J.JVIR.2024.10.034","volume":"36","author":"R Salem","year":"2025","unstructured":"Salem R, Kwong AJ, Kim N, Sze DY, Mehta N. Yttrium-90 radioembolization has become the most utilized bridging treatment for liver transplant candidates in the united States. J Vascular Interventional Radiology: JVIR. 2025;36:362\u20133. https:\/\/doi.org\/10.1016\/J.JVIR.2024.10.034.","journal-title":"J Vascular Interventional Radiology: JVIR"},{"key":"7471_CR5","unstructured":"Data. - OPTN."},{"key":"7471_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/HEP.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (Baltimore MD). 2014;60:192\u2013201. https:\/\/doi.org\/10.1002\/HEP.27057.","journal-title":"Hepatology (Baltimore MD)"},{"key":"7471_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","volume":"48","author":"A Gabr","year":"2021","unstructured":"Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48:580\u20133. https:\/\/doi.org\/10.1007\/s00259-020-04976-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7471_CR8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/J.JVIR.2020.12.019","volume":"32","author":"B Toskich","year":"2021","unstructured":"Toskich B, Vidal LL, Olson MT, Lewis JT, LeGout JD, Sella DM, et al. Pathologic response of hepatocellular carcinoma treated with Yttrium-90 glass microsphere radiation segmentectomy prior to liver transplantation: A validation study. J Vascular Interventional Radiology: JVIR. 2021;32:518\u2013e261. https:\/\/doi.org\/10.1016\/J.JVIR.2020.12.019.","journal-title":"J Vascular Interventional Radiology: JVIR"},{"key":"7471_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/J.JVIR.2023.12.009","volume":"35","author":"M Mosenthal","year":"2024","unstructured":"Mosenthal M, Adams W, Cotler S, Ding X, Borge M, Malamis A, et al. Locoregional therapies for hepatocellular carcinoma prior to liver transplant: comparative pathologic necrosis, radiologic response, and recurrence. J Vascular Interventional Radiology: JVIR. 2024;35:506\u201314. https:\/\/doi.org\/10.1016\/J.JVIR.2023.12.009.","journal-title":"J Vascular Interventional Radiology: JVIR"},{"key":"7471_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/HEP.22747","volume":"49","author":"A Riaz","year":"2009","unstructured":"Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Spear GG, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology (Baltimore MD). 2009;49:1185\u201393. https:\/\/doi.org\/10.1002\/HEP.22747.","journal-title":"Hepatology (Baltimore MD)"},{"key":"7471_CR11","doi-asserted-by":"publisher","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology (Baltimore, Md). 2021;74:2342\u201352. https:\/\/doi.org\/10.1002\/HEP.31819","DOI":"10.1002\/HEP.31819"},{"key":"7471_CR12","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/S00259-023-06111-9","volume":"50","author":"N Kokabi","year":"2023","unstructured":"Kokabi N, Arndt-Webster L, Chen B, Brandon D, Sethi I, Davarpanahfakhr A, et al. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. Eur J Nucl Med Mol Imaging. 2023;50:1743\u201352. https:\/\/doi.org\/10.1007\/S00259-023-06111-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7471_CR13","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/J.JVIR.2023.02.030","volume":"34","author":"A Villalobos","year":"2023","unstructured":"Villalobos A, Arndt L, Cheng B, Dabbous H, Loya M, Majdalany B, et al. Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: A comparative study of the effectiveness, safety, and dosimetry of Glass-Based versus Resin-Based microspheres. J Vascular Interventional Radiology: JVIR. 2023;34:1226\u201334. https:\/\/doi.org\/10.1016\/J.JVIR.2023.02.030.","journal-title":"J Vascular Interventional Radiology: JVIR"},{"key":"7471_CR14","doi-asserted-by":"publisher","unstructured":"Sarwar A, Malik MS, Vo NH, Tsai LL, Tahir MM, Curry MP, et al. Efficacy and safety of radiation segmentectomy with 90Y resin microspheres for hepatocellular carcinoma. Radiology. 2024;311. https:\/\/doi.org\/10.1148\/RADIOL.231386.","DOI":"10.1148\/RADIOL.231386"},{"key":"7471_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/S00268-016-3682-Z","volume":"41","author":"GM Ettorre","year":"2017","unstructured":"Ettorre GM, Levi Sandri GB, Laurenzi A, Colasanti M, Meniconi RL, Lionetti R, et al. Yttrium-90 radioembolization for hepatocellular carcinoma prior to liver transplantation. World J Surg. 2017;41:241\u20139. https:\/\/doi.org\/10.1007\/S00268-016-3682-Z.","journal-title":"World J Surg"},{"key":"7471_CR16","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/LT.26257","volume":"27","author":"M Serenari","year":"2021","unstructured":"Serenari M, Cappelli A, Cucchetti A, Mosconi C, Strigari L, Monari F, et al. Deceased donor liver transplantation after radioembolization for hepatocellular carcinoma and portal vein tumoral thrombosis: A pilot study. Liver Transpl. 2021;27:1758. https:\/\/doi.org\/10.1002\/LT.26257.","journal-title":"Liver Transpl"},{"key":"7471_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/J.JVIR.2024.10.021","author":"L Bonne","year":"2024","unstructured":"Bonne L, Deroose CM, Verslype C, Monbaliu D, Dekervel J, Van Laeken C, et al. Resin-Based Yttrium-90 radioembolization as a bridging or downstaging treatment to liver transplantation for hepatocellular carcinoma. J Vascular Interventional Radiology: JVIR. 2024. https:\/\/doi.org\/10.1016\/J.JVIR.2024.10.021.","journal-title":"J Vascular Interventional Radiology: JVIR"},{"key":"7471_CR18","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/hep.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365. https:\/\/doi.org\/10.1097\/hep.0000000000000466.","journal-title":"Hepatology"},{"key":"7471_CR19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/S00270-022-03139-6","volume":"45","author":"AWP Maxwell","year":"2022","unstructured":"Maxwell AWP, Mendoza HG, Sellitti MJ, Camacho JC, Deipolyi AR, Ziv E, et al. Optimizing 90Y particle density improves outcomes after radioembolization. Cardiovasc Interv Radiol. 2022;45:958\u201369. https:\/\/doi.org\/10.1007\/S00270-022-03139-6.","journal-title":"Cardiovasc Interv Radiol"},{"key":"7471_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.31318","volume":"73","author":"A Gabr","year":"2021","unstructured":"Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K, et al. Liver transplantation following Yttrium-90 radioembolization: 15-Year experience in 207-Patient cohort. Hepatology. 2021;73:998\u20131010. https:\/\/doi.org\/10.1002\/hep.31318.","journal-title":"Hepatology"},{"key":"7471_CR21","doi-asserted-by":"publisher","unstructured":"Taswell CS, Studenski M, Pennix T, Stover B, Georgiou M, Venkat S, et al. For hepatocellular carcinoma treated with Yttrium-90 microspheres, dose volumetrics on Post-Treatment Bremsstrahlung SPECT\/CT predict clinical outcomes. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15030645.","DOI":"10.3390\/cancers15030645"},{"key":"7471_CR22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/J.CGH.2021.07.048","volume":"20","author":"AJ Kwong","year":"2022","unstructured":"Kwong AJ, Ghaziani TT, Yao F, Sze D, Mannalithara A, Mehta N. National trends and waitlist outcomes of locoregional therapy among liver transplant candidates with hepatocellular carcinoma in the united States. Clin Gastroenterol Hepatol. 2022;20:1142\u2013e504. https:\/\/doi.org\/10.1016\/J.CGH.2021.07.048.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7471_CR23","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","volume":"271","author":"J Dinorcia","year":"2020","unstructured":"Dinorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, et al. Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US multicenter HCC transplant consortium. Ann Surg. 2020;271:616\u201324. https:\/\/doi.org\/10.1097\/SLA.0000000000003253.","journal-title":"Ann Surg"},{"key":"7471_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/J.JVIR.2022.05.019","volume":"33","author":"AB Couillard","year":"2022","unstructured":"Couillard AB, Knott EA, Zlevor AM, Mezrich JD, Cristescu MM, Agarwal P, et al. Microwave ablation as bridging to liver transplant for patients with hepatocellular carcinoma: A Single-Center retrospective analysis. J Vascular Interventional Radiology: JVIR. 2022;33:1045\u201353. https:\/\/doi.org\/10.1016\/J.JVIR.2022.05.019.","journal-title":"J Vascular Interventional Radiology: JVIR"},{"key":"7471_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/HEP.20688","volume":"41","author":"DSK Lu","year":"2005","unstructured":"Lu DSK, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a Bridge to liver transplantation. Hepatology (Baltimore MD). 2005;41:1130\u20137. https:\/\/doi.org\/10.1002\/HEP.20688.","journal-title":"Hepatology (Baltimore MD)"},{"key":"7471_CR26","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/S00270-021-02873-7","volume":"44","author":"A Som","year":"2021","unstructured":"Som A, Reid NJ, DiCapua J, Cochran RL, An T, Uppot R, et al. Microwave ablation as bridging therapy for patients with hepatocellular carcinoma awaiting liver transplant: A single center experience. Cardiovasc Interv Radiol. 2021;44:1749\u201354. https:\/\/doi.org\/10.1007\/S00270-021-02873-7.","journal-title":"Cardiovasc Interv Radiol"},{"key":"7471_CR27","doi-asserted-by":"publisher","unstructured":"Crocetti L, Bozzi E, Scalise P, Bargellini I, Lorenzoni G, Ghinolfi D, et al. Locoregional treatments for bridging and downstaging HCC to liver transplantation. Cancers. 2021;13. https:\/\/doi.org\/10.3390\/CANCERS13215558.","DOI":"10.3390\/CANCERS13215558"},{"key":"7471_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2025.05.009","author":"A Sher","year":"2025","unstructured":"Sher A, Todd RI, Shilo D, Garcia-Reyes KI, Bishay VL, Patel RI, et al. Histopathologic response and oncologic outcomes after segmental and subsegmental transarterial chemoembolization and radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2025. https:\/\/doi.org\/10.1016\/j.jvir.2025.05.009.","journal-title":"J Vasc Interv Radiol"},{"key":"7471_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1399-0012.2006.00538.x","volume":"20","author":"AP Martin","year":"2006","unstructured":"Martin AP, Goldstein RM, Dempster J, Netto GJ, Katabi N, Derrick HC, et al. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation\u2013a clinical and histological examination. Clin Transpl. 2006;20:695\u2013705. https:\/\/doi.org\/10.1111\/j.1399-0012.2006.00538.x.","journal-title":"Clin Transpl"},{"key":"7471_CR30","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1007\/S00259-022-05776-Y","volume":"49","author":"SA Montazeri","year":"2022","unstructured":"Montazeri SA, De la Garza-Ramos C, Lewis AR, Lewis JT, LeGout JD, Sella DM, et al. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging. 2022;49:3892\u20137. https:\/\/doi.org\/10.1007\/S00259-022-05776-Y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7471_CR31","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Sanju\u00e1n JC, Gonz\u00e1lez F, G\u00f3mez-Fleitas M. Radiofrequency ablation must be assessed by pathological methods. Hepatology. 2010;51:723; author reply\u2013\u20094. https:\/\/doi.org\/10.1002\/hep.23454","DOI":"10.1002\/hep.23454"},{"key":"7471_CR32","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00268-008-9559-z","volume":"32","author":"JC Rodr\u00edguez-Sanju\u00e1n","year":"2008","unstructured":"Rodr\u00edguez-Sanju\u00e1n JC, Gonz\u00e1lez F, Juanco C, Herrera LA, L\u00f3pez-Bautista M, Gonz\u00e1lez-Noriega M, et al. Radiological and pathological assessment of hepatocellular carcinoma response to radiofrequency. A study on removed liver after transplantation. World J Surg. 2008;32:1489\u201394. https:\/\/doi.org\/10.1007\/s00268-008-9559-z.","journal-title":"World J Surg"},{"key":"7471_CR33","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.2214\/ajr.04.1927","volume":"186","author":"PY Brillet","year":"2006","unstructured":"Brillet PY, Paradis V, Brancatelli G, Rangheard AS, Consigny Y, Plessier A, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol. 2006;186:S296\u2013305. https:\/\/doi.org\/10.2214\/ajr.04.1927.","journal-title":"AJR Am J Roentgenol"},{"key":"7471_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/hepr.13407","volume":"50","author":"Y Minami","year":"2020","unstructured":"Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, et al. Radiofrequency ablation for hepatocellular carcinoma: clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability. Hepatol Res. 2020;50:67\u201374. https:\/\/doi.org\/10.1111\/hepr.13407.","journal-title":"Hepatol Res"},{"key":"7471_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.21037\/HBSN-22-184","volume":"12","author":"MA Meerun","year":"2023","unstructured":"Meerun MA, Allimant C, Rivi\u00e8re B, Herrero A, Panaro F, Assenat E, et al. Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery. Hepatobiliary Surg Nutr. 2023;12:351\u201365. https:\/\/doi.org\/10.21037\/HBSN-22-184.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"7471_CR36","doi-asserted-by":"publisher","unstructured":"Tahir MM, Ali A, Nasser I, Dinh DC, Catana AM, Bullock A, et al. Hepatocellular carcinoma with vascular invasion treated with resin Yttrium-90 transarterial radioembolization using single compartment dosimetry. Cardiovasc Interv Radiol. 2025;1\u20138. https:\/\/doi.org\/10.1007\/S00270-024-03933-4\/METRICS.","DOI":"10.1007\/S00270-024-03933-4\/METRICS"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07471-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07471-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07471-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:46:26Z","timestamp":1769222786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07471-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7471"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07471-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Dana-Farber\/Harvard Cancer Center (IRB#20\u2013466).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent was waived because of the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"A.S. Grants or contracts from Sirtex Medical, consulting fees from ABK Biomedical and Boston Scientific, participation on a medical advisory board for Sirtex Medical and Boston Scientific, chair of economics for the Society of Interventional Radiology. A.B. advisory fees from Sirtex. M.A. consulting fees form Sirtex Medical and served on a medical advisory board for Boston Scientific. J.L.W., I.N., M.O., H.B., D.D., M.C., D.E., M.D. and J.A.P declare they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}